AR125304A1 - Compuestos de oxazepina acíclicos y usos de los mismos - Google Patents
Compuestos de oxazepina acíclicos y usos de los mismosInfo
- Publication number
- AR125304A1 AR125304A1 ARP220100858A ARP220100858A AR125304A1 AR 125304 A1 AR125304 A1 AR 125304A1 AR P220100858 A ARP220100858 A AR P220100858A AR P220100858 A ARP220100858 A AR P220100858A AR 125304 A1 AR125304 A1 AR 125304A1
- Authority
- AR
- Argentina
- Prior art keywords
- acyclic
- oxazepine compounds
- oxazepine
- compounds
- atropisomer
- Prior art date
Links
- 150000000221 oxazepines Chemical class 0.000 title 1
- -1 Acyclic oxazepine compounds Chemical class 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021085959 | 2021-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125304A1 true AR125304A1 (es) | 2023-07-05 |
Family
ID=81387302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100858A AR125304A1 (es) | 2021-04-08 | 2022-04-06 | Compuestos de oxazepina acíclicos y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240383915A1 (https=) |
| EP (1) | EP4320132A1 (https=) |
| JP (1) | JP2024513881A (https=) |
| KR (1) | KR20230167386A (https=) |
| CN (1) | CN117083279A (https=) |
| AR (1) | AR125304A1 (https=) |
| AU (1) | AU2022254674A1 (https=) |
| BR (1) | BR112023020773A2 (https=) |
| CA (1) | CA3215949A1 (https=) |
| MX (1) | MX2023011873A (https=) |
| TW (1) | TWI868441B (https=) |
| WO (1) | WO2022216762A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| AU2023320914A1 (en) * | 2022-08-11 | 2025-02-27 | Beone Medicines I Gmbh | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| JP2025535294A (ja) * | 2022-10-18 | 2025-10-24 | アイディーエンス カンパニー リミテッド | 新規なトリヘテロ環化合物 |
| JP2025535367A (ja) * | 2022-10-19 | 2025-10-24 | ジェネンテック， インコーポレイテッド | ６－アザ部分を含むオキサゼピン化合物およびその使用 |
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2024153180A1 (zh) * | 2023-01-18 | 2024-07-25 | 上海艾力斯医药科技股份有限公司 | 杂环类化合物、其药物组合物及其用途 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2024197503A1 (en) * | 2023-03-27 | 2024-10-03 | Nikang Therapeutics , Inc. | Tricyclic derivatives as kras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| EP4713330A1 (en) * | 2023-05-16 | 2026-03-25 | HUTCHMED Limited | Tricyclic compounds and uses thereof |
| CN121605110A (zh) * | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| AU2024307234A1 (en) * | 2023-06-30 | 2026-01-29 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| CN116903499B (zh) * | 2023-07-11 | 2025-05-30 | 上海应用技术大学 | 无水氟磺酰基二氟乙酸铜盐及其制备方法与应用 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024323424A1 (en) | 2023-08-17 | 2026-03-05 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250163079A1 (en) * | 2023-11-01 | 2025-05-22 | Incyte Corporation | Kras inhibitors |
| WO2025111586A1 (en) | 2023-11-22 | 2025-05-30 | Genentech, Inc. | Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d |
| TW202527946A (zh) * | 2023-12-19 | 2025-07-16 | 大陸商正大天晴藥業集團股份有限公司 | 三并環類化合物及其醫藥用途 |
| WO2025167948A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海齐鲁制药研究中心有限公司 | 嘧啶并大环类kras抑制剂 |
| WO2025168072A1 (en) * | 2024-02-08 | 2025-08-14 | Beigene (Suzhou) Co., Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| CR20190157A (es) * | 2016-08-31 | 2019-08-13 | Agios Pharmaceuticals Inc | Inhibidores de procesos metabólicos celulares |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| ES3010507T3 (en) * | 2019-03-05 | 2025-04-03 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| WO2021063346A1 (zh) * | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
-
2022
- 2022-04-06 WO PCT/US2022/023573 patent/WO2022216762A1/en not_active Ceased
- 2022-04-06 MX MX2023011873A patent/MX2023011873A/es unknown
- 2022-04-06 EP EP22719149.1A patent/EP4320132A1/en active Pending
- 2022-04-06 JP JP2023561271A patent/JP2024513881A/ja active Pending
- 2022-04-06 BR BR112023020773A patent/BR112023020773A2/pt unknown
- 2022-04-06 TW TW111113063A patent/TWI868441B/zh active
- 2022-04-06 US US18/554,438 patent/US20240383915A1/en active Pending
- 2022-04-06 CN CN202280026974.XA patent/CN117083279A/zh active Pending
- 2022-04-06 AR ARP220100858A patent/AR125304A1/es unknown
- 2022-04-06 AU AU2022254674A patent/AU2022254674A1/en active Pending
- 2022-04-06 CA CA3215949A patent/CA3215949A1/en active Pending
- 2022-04-06 KR KR1020237037698A patent/KR20230167386A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202304934A (zh) | 2023-02-01 |
| JP2024513881A (ja) | 2024-03-27 |
| AU2022254674A1 (en) | 2023-10-12 |
| CN117083279A (zh) | 2023-11-17 |
| KR20230167386A (ko) | 2023-12-08 |
| US20240383915A1 (en) | 2024-11-21 |
| MX2023011873A (es) | 2023-10-17 |
| CA3215949A1 (en) | 2022-10-13 |
| WO2022216762A1 (en) | 2022-10-13 |
| TWI868441B (zh) | 2025-01-01 |
| BR112023020773A2 (pt) | 2024-01-30 |
| EP4320132A1 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125304A1 (es) | Compuestos de oxazepina acíclicos y usos de los mismos | |
| AR130727A1 (es) | Compuestos tricíclicos y sus usos | |
| AR122628A1 (es) | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 | |
| AR054809A1 (es) | Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa | |
| AR121226A1 (es) | Compuestos y usos de estos | |
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| ES2196772T3 (es) | Compuestos amino ciclicos. | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR121777A1 (es) | Derivados de diamina macrocíclica como inhibidores de ent para el tratamiento de cánceres, y combinación de estos con antagonistas del receptor de adenosina | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR008290A1 (es) | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. | |
| AR045805A1 (es) | Quinolonas y naftridonas 7- amino alquidenil - heterociclicas | |
| AR131158A1 (es) | Compuestos que inhiben la pkmyt1 | |
| ES2095942T3 (es) | Derivados de bencenoacetamida inhibidores del vih. | |
| AR124008A1 (es) | 1,4-diazepanonas bicíclicas y sus usos terapéuticos | |
| AR131278A1 (es) | Compuestos novedosos | |
| AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. | |
| AR119784A1 (es) | Agentes antipalúdicos | |
| PE20031038A1 (es) | Compuestos triciclicos como inhibidores de la farnesil proteina transferasa | |
| CL2024001298A1 (es) | Compuestos de cd73 | |
| AR128494A1 (es) | Compuestos heterocíclicos, composiciones de los mismos y métodos de tratamiento con los mismos | |
| ES2075976T3 (es) | Derivados de aminoacido y su empleo como agentes antiviricos. | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo |